Skip to content
Take logo

Take

TAKE NSE
₹11.42 +0.54 (+4.96%)
P/E
13.13
View as Markdown
MCP
Close 4 Nov 2026 ₹11.42 −11.78 −50.8% 1Y
Start ₹23.20

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
18.50%
Debt to Equity
0.00
EPS (TTM)
₹0.87
Book Value
₹2.10
Market Cap
—
P/E (TTM)
13.13
P/B
5.44
ROE
16.50%
Dividend Yield
0.00%
EBITDA
₹4.80 Cr
52W High
₹50.14
52W Low
₹9.88
Day Range
₹10.91 – ₹11.42
Volume
1,47,031

Peer Comparison

Healthcare › Healthcare Technology › Healthcare Research, Analytics & Technology

Take peer comparison
Syngene International
₹417.5076.05₹16,536 Cr3.470.31%7.78%9.99%₹3,600 Cr₹221 Cr
Indegene
₹617.1037.04₹14,947 Cr4.430.37%14.40%18.80%₹3,813 Cr₹401 Cr
Suven Life Sciences
₹276.10—₹7,549 Cr11.390.00%−81.50%−79.50%₹9 Cr−₹353 Cr
Vimta Labs
₹497.8527.89₹2,195 Cr4.530.41%18.90%25.20%₹419 Cr₹80 Cr
Fabtech Technologies
₹132.309.94₹589 Cr1.340.46%12.50%13.60%₹418 Cr₹49 Cr
Take (this company)
₹11.4213.13₹161 Cr5.440.00%16.50%18.50%₹85 Cr₹13 Cr
Median 6 companies₹346.8027.89₹4,872 Cr4.480.34%13.45%16.05%₹419 Cr₹64 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 89/100

Category scores

Quality
32
Poor
Returns, margins, earnings quality 24% weight
Valuation
42
Weak
Cheap vs sector & own history 26% weight
Financial Health
90
Strong
Solvency, leverage, coverage 10% weight
Momentum
3
Poor
Trend strength, vol-adjusted 13% weight
Ownership
50
Average
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

7
  • Stock is trading at 5.47 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -41.2% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of -47.0% over last 3 years.
  • Earnings include an other income of Rs.14.9 Cr.
  • Working capital days have increased from -2,718 days to 123 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1054
OscillatorsNeutral252
Moving AveragesStrong Bearish802

Key readings

RSI (14)
43.31
Neutral
MACD (12,26,9)
−1.00
Bullish
SMA (50)
13.95
Bearish
SMA (200)
29.07
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−25.53%
5Y−41.29%
3Y−34.14%
1YZero base
TTMZero base

Net profit

Net profit growth by window
10Y−21.58%
5YTurned to profit
3YTurned to profit
1Y−70.27%
TTM−68.20%

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YTurned negative
3YTurned negative
1YOutflow narrowed by ₹12 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−24.38 pp
5Y+5.73 pp
3Y+6.35 pp
1YNo sales
TTMNo sales

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,345 Cr
Mar 2018₹1,587 Cr
Mar 2019₹2,039 Cr
Mar 2020₹2,213 Cr
Mar 2021₹774 Cr
Mar 2022₹655 Cr
Mar 2023₹189 Cr
Mar 2024₹4.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹54.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹146 Cr
Mar 2018₹160 Cr
Mar 2019₹178 Cr
Mar 2020−₹11.00 Cr
Mar 2021−₹450 Cr
Mar 2022−₹782 Cr
Mar 2023−₹100 Cr
Mar 2024−₹120 Cr
Mar 2025₹37.00 Cr
Mar 2026₹11.00 Cr

Quarterly Results

₹ Cr
TAKE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
3.55
0.05
0
0
0
0
0
0
0
0
0
54.19
30.37
Expenses
5.5
1.5
1.98
15.76
2.22
0.9
2.89
1.15
0.44
0.3
0.35
55.01
30.64
Operating Profit
−1.95
−1.45
−1.98
−15.76
−2.22
−0.9
−2.89
−1.15
−0.44
−0.3
−0.35
−0.82
−0.27
OPM %
−54.93%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
—
—
—
—
—
—
—
—
—
−1.51%
−0.89%
Other Income
−2.25
0.41
4.07
−93.7
−0.97
−0.23
51.31
−3.48
−0.29
6.92
1.46
5.18
1.33
Interest
0.64
0.56
0.54
0.54
0.49
0.5
0.73
0.24
0.18
0.17
0
0
0
Depreciation
0.3
0.3
0.11
0.01
0.01
0.01
0.01
0.01
0
0
0
0
0
PBT
−5.14
−1.9
1.44
−110
−3.69
−1.64
47.68
−4.88
−0.91
6.45
1.11
4.36
1.06
Tax %
3.5%
−18.42%
248.61%
0.55%
1.63%
−3.66%
0%
0%
0%
2.48%
0%
0%
0%
Net Profit
−5.32
−1.55
−2.14
−111
−3.75
−1.58
47.68
−4.88
−0.91
6.29
1.11
4.36
1.06
EPS (₹)
−0.36
−0.1
−0.14
−7.48
−0.25
−0.11
3.22
−0.33
−0.06
0.43
0.08
0.29
0.07

Profit & Loss

₹ Cr
TAKE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
730
1,030
1,345
1,587
2,039
2,213
774
655
189
4
0
54
85
Expenses
581
817
1,082
1,281
1,655
2,044
847
648
208
24
7
56
86
Operating Profit
149
213
262
307
384
169
−73
7
−19
−20
−7
−2
−2
OPM %
20%
21%
20%
19%
19%
8%
−9%
1.1%
−10%
−569%
—
−3.5%
−2.1%
Other Income
8
21
13
6
11
26
−211
−677
−56
−92
47
13
15
Interest
13
15
23
21
25
41
37
29
7
2
2
0
0
Depreciation
60
74
87
104
154
167
115
80
17
1
0
0
0
PBT
85
145
165
188
216
−13
−437
−779
−99
−116
37
11
13
Tax %
6%
14%
11%
15%
17%
−15%
3%
0%
2%
3%
0%
1%
—
Net Profit
80
125
146
160
178
−11
−450
−782
−100
−120
37
11
13
EPS (₹)
5.71
9.78
10.74
10.85
11.99
−0.84
−30.56
−52.88
−6.78
−8.09
2.53
0.73
0.87
Div. Payout %
17%
10%
9%
15%
8%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
TAKE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
13
15
15
15
15
15
15
15
15
15
Reserves
512
619
898
1,314
1,504
1,561
1,110
166
94
−24
6
16
Borrowings
209
336
237
323
474
553
514
59
46
37
0
0
Other Liabilities
189
246
221
189
339
336
187
984
69
60
16
5
Total Liabilities
922
1,214
1,369
1,840
2,331
2,465
1,826
1,223
224
88
36
36
Fixed Assets
359
543
554
589
1,091
1,234
934
101
73
30
0
0
CWIP
17
3
21
42
41
1
0
3
11
0
0
0
Investments
6
21
10
59
10
18
7
0
0
0
0
0
Other Assets
541
647
785
1,150
1,188
1,213
885
1,119
140
58
36
36
Total Assets
922
1,214
1,369
1,840
2,331
2,465
1,826
1,223
224
88
36
36

Cash Flow

₹ Cr
TAKE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
74
151
56
121
104
211
135
30
20
9
−16
−4
Investing
−14
−292
−130
−179
−474
−233
−57
15
−3
−7
22
2
Financing
−11
111
56
302
100
21
−84
−55
−36
−12
−3
−1
Net Cash Flow
49
−30
−18
243
−270
−2
−6
−10
−18
−10
3
−3
Free Cash Flow
46
35
−30
39
−23
54
133
−2
−12
2
−16
−4
CFO/EBITDA
52
76
26
44
30
156
−212
704
−114
−43
217
208

Ratios

TAKE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
120
107
118
108
94
116
205
45
58
715
—
1
Inventory Days
—
—
—
—
—
—
—
—
—
—
—
0
Cash Conversion Cycle
120
107
118
108
94
116
205
45
58
715
—
1
Working Capital Days
42
19
90
85
67
80
140
28
−42
−5,559
—
123
ROCE %
13%
16%
17%
15%
13%
1%
−9%
−6%
−14%
−22%
11%
19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Take insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Others 68.73%
  • Public 31.05%
  • FIIs 0.21%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Take

What does Take Ltd do?
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services
Where is Take Ltd (TAKE) listed?
Take Ltd trades as TAKE on the NSE and under code 532890 on the BSE.
Which sector does Take Ltd belong to?
Take Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the PE ratio of Take Ltd?
Take Ltd trades at a PE ratio of 13.13 as of 4 Nov 2026, on earnings per share of ₹0.87, against a book value of ₹2.1 per share.
What is the 52-week high and low of Take Ltd?
Over the last 52 weeks Take Ltd has traded between ₹9.88 and ₹50.14 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Take Ltd?
Take Ltd reported a return on equity of 16.50%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services

Website takesolutions.com
CEO Ms. Sonia Bhimrajka
Employees 2
Listed 27 Aug 2007
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TAKE.md for Take Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month